WuXi Biologics, Wuxi

WuXi Biologics concentrates a major share of the world's biopharmaceutical outsourcing (antibodies, ADCs, bispecifics), with nearly half of its 2025 signings for American clients. The BIOSECURE Act, carried by the NDAA in late 2025 to curb reliance on Chinese contract manufacturers, has triggered the largest capacity redeployment since the globalisation of the 2000s. The weaning remains largely theoretical, so scarce are certified alternatives in the short term.